A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era

Author:

Robinson Hannah R.12,Qi Junpeng3,Cook Erika M.1,Nichols Cydney1,Dadashian Eman L.1,Underbayev Chingiz1,Herman Sarah E. M.1,Saba Nakhle S.4,Keyvanfar Keyvan1,Sun Clare1ORCID,Ahn Inhye E.1,Baskar Sivasubramanian1,Rader Christoph3,Wiestner Adrian1

Affiliation:

1. Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD;

2. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH;

3. Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL; and

4. Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA

Abstract

Key Points A CD19/CD3 single-chain Fv-Fc bsAb mediated potent killing of CLL cells by autologous T cells in vitro and in vivo. bsAb-mediated cytotoxicity was enhanced by prior therapy with ibrutinib and extended to ibrutinib-resistant disease.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3